TI
OVID icon

tru Independence’s Ovid Therapeutics OVID Stock Holding History

tru Independence’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-800
Closed -$5K – 691
2020
Q2 		$5K Buy
+800
New +$3.74K ﹤0.01% 703

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

tru Independence's OVID Position: Q3 2020 in Review

tru Independence sold out of Ovid Therapeutics (OVID) in Q3 2020, closing a stake of 800 shares — an estimated $5K sold.

tru Independence first reported a position in OVID in Q2 2020 and held it in 1 quarter. The position peaked at $5K in Q2 2020. 91 funds tracked by Wall St. Rank hold OVID as of Q3 2020.

  • tru Independence reported no remaining Ovid Therapeutics position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 800 Ovid Therapeutics shares in Q3 2020, an estimated $5K.
  • tru Independence first reported a position in Ovid Therapeutics in Q2 2020 and held it in 1 quarter.
  • tru Independence's Ovid Therapeutics position peaked at $5K in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.